In Vitro Cell-Based Bioassays for Screening and Comparison of the TNFα and IL-17A Inhibitors

Based on primary human cell cultures obtained from tissues of juvenile donors, bioassays to assess in vitro the biological activity of TNF-α and IL-17A inhibitors have been developed. The fibrotest-bioassay included the quantification of proinflammatory cytokines MCP-1, IL-6 and IL-8 in human foreskin fibroblasts (HFF) stimulated with TNF-α and IL-17A. The chondrotest-bioassay is based on a cartilage-derived cell culture obtained from six-fingered juvenile donors with polydactyly. Using the chondrotest-bioassay, the biological activities of the TNF-α inhibitor Remicade® (MSD, Ireland) as an original commercial drug and its biosimilar Infliximab® (BIOCAD, Russia) were compared.